Participants in the 14-week trial must be 18 years or older and in good general health, meet diagnostic criteria for opioid use disorder and be willing to be randomly assigned one of the two ...

Buprenorphine comes in several forms including a monthly injection and daily oral tablets and films. The injection is still under patent, so it costs about $2,000, but it is covered by Medicaid.

For a patient who does not make progress with a dose increase to 32 milligrams, the clinician might consider a different treatment plan, such as a 30-day buprenorphine injection, which can provide ...

MOUD claims included pharmacy claims for buprenorphine, medical claims for administration of buprenorphine during outpatient visits (for example, extended-release buprenorphine injection ...

SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use [package insert]. North Chesterfield, VA: Indivior PLC; 2025. Jones AK, Ngaimisi E, Gopalakrishnan M, Young MA, Laffont CM.

Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved label changes for SUBLOCADE® including a ...

Opioids are dangerous substances, but overdoses can be reversed if prompt action is taken. Having naloxone around people who use opioids in whatever form can and does save lives. All people using such ...

Genital drug injection appears to be rare, but there are a number of recorded cases in the medical literature. What do we know about this extreme behavior?

Extended-release 7-day injectable buprenorphine is acceptable, well tolerated, and safe in patients with minimal to mild opioid withdrawal.